CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 60 enrolled
Drug / intervention
Atorvastatin +1 moredrug
Likely dose
Atorvastatin 40mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01096875
NCT01096875Phase 4Completed
CompareCT.gov

Assessment of the Effects of Atorvastatin on Endothelial Progenitor Cells After Coronary ByPass Surgery; A Randomized Controlled Trial

Ankara University·interventional·Posted Mar 31, 2010·Updated Jul 9, 2014

In Brief

A Phase 4 clinical trial evaluating Atorvastatin and Placebo for Coronary Artery Bypass Surgery and Elective Surgical Procedure. Completed, enrolled 60 participants across 1 site.

Detailed Summary

Experimental data have demonstrated favourable effects of statins on endothelial progenitor cell (EPC) mobilization from the bone marrow, and cardiac homing. The purpose of the present prospective randomized controlled trial is to determine the effects of aggressive atorvastatin treatment (40 mg daily 2-weeks prior to surgery) on the number of endothelial progenitor cells (EPCs) after cardiopulmonary bypass by comparing with placebo.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCoronary Artery Bypass Surgery, Elective Surgical Procedure
CountriesTurkey (Türkiye)
CollaboratorsTurkish Society of Hematology

Timeline

Phase 4CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedMar 31, 2010
Enrollment StartFeb 1, 2010
Primary CompletionJul 1, 2010
Study CompletionOct 1, 2010
TodayJul 2, 2026
Enrollment to primary: 5 monthsPosted 16.3 years ago

Interventions

Atorvastatindrug

40mg/day once daily for two weeks prior to surgery

Placebodrug

1tb/day once daily for two weeks prior to surgery